Table 2.
Point estimates of outcomes considering the HLA-C matching score
| HLA-C Score | N |
Overall Survival at 5 years |
Disease-Free Survival at 5 years |
Relapse at 5 years |
Non-Relapse Mortality at 2 years |
||||
|---|---|---|---|---|---|---|---|---|---|
| Estimate (CI 95%) |
P-value | Estimate (CI 95%) |
P-value | Estimate (CI 95%) |
P-value | Estimate (CI 95%) |
P-value | ||
| 0/4 | 57 | 34% (21–46%) |
0.25 | 29% (18–41%) |
0.45 | 32% (19–45%) |
0.29 | 37% (24–50%) |
0.01 |
| 1/4 | 62 | 33% (21–45%) |
24% (14–36%) |
33% (20–46%) |
40% (28–53%) |
||||
| 2/4 | 211 | 37% (30–44%) |
32% (26–39%) |
27% (20–33%) |
36% (29–43%) |
||||
| 3/4 | 108 | 45% (35–54%) |
36% (27–46%) |
40% (30–50%) |
22% (14–30%) |
||||
| 4/4 | 77 | 47% (35–58%) |
38% (27–49%) |
42% (30–55%) |
19% (11–28%) |
||||
| HLA-C Score | N | Acute GVHD 100 days |
Chronic GVHD 2 years |
Neutrophil Recovery 42 days |
Platelet Recovery 6 months |
||||
|---|---|---|---|---|---|---|---|---|---|
| Estimate (CI 95%) |
P-value | Estimate (CI 95%) |
P-value | Estimate (CI 95%) |
P-value | ||||
| 0/4 | 57 | 40% (27–54%) |
0.92 | 26% (14–38%) |
0.40 | 87% (77–94%) |
0.01 | 65% (49–80%) |
0.05 |
| 1/4 | 62 | 44% (31–56%) |
18% (8–28%) |
89% (80–96%) |
63% (48–78%) |
||||
| 2/4 | 211 | 41% (34–48% |
22% (16–28%) |
86% (81–90%) |
69% (60–77%) |
||||
| 3/4 | 108 | 40% (30–49%) |
17% (10–24%) |
89% (82–94%) |
73% (62–84%) |
||||
| 4/4 | 77 | 44% (33–56%) |
21% (12–30%) |
90% (83–96%) |
73% (59–86%) |
||||
Abbreviations: HLA, human leukocyte antigen; CI, confidence interval; GVHD, graft-vs.-host disease.